Search

Your search keyword '"Sedlaczek, Oliver"' showing total 190 results
Start Over Author "Sedlaczek, Oliver"
190 results on '"Sedlaczek, Oliver"'

2. Diffusion-weighted MRI-guided needle biopsies permit quantitative tumor heterogeneity assessment and cell load estimation

Author

Yin, Yi, Breuhahn, Kai, Kauczor, Hans-Ulrich, Sedlaczek, Oliver, Vignon-Clementel, Irene E., and Drasdo, Dirk

Subjects
Electrical Engineering and Systems Science - Image and Video Processing, Physics - Medical Physics
Abstract

Quantitative information on tumor heterogeneity and cell load could assist in designing effective and refined personalized treatment strategies. It was recently shown by us that such information can be inferred from the diffusion parameter D derived from the diffusion-weighted MRI (DWI) if a relation between D and cell density can be established. However, such relation cannot a priori be assumed to be constant for all patients and tumor types. Hence to assist in clinical decisions in palliative settings, the relation needs to be established without tumor resection. It is here demonstrated that biopsies may contain sufficient information for this purpose if the localization of biopsies is chosen as systematically elaborated in this paper. A superpixel-based method for automated optimal localization of biopsies from the DWI D-map is proposed. The performance of the DWI-guided procedure is evaluated by extensive simulations of biopsies. Needle biopsies yield sufficient histological information to establish a quantitative relationship between D-value and cell density, provided they are taken from regions with high, intermediate, and low D-value in DWI. The automated localization of the biopsy regions is demonstrated from a NSCLC patient tumor. In this case, even two or three biopsies give a reasonable estimate. Simulations of needle biopsies under different conditions indicate that the DWI-guidance highly improves the estimation results. Tumor cellularity and heterogeneity in solid tumors may be reliably investigated from DWI and a few needle biopsies that are sampled in regions of well-separated D-values, excluding adipose tissue. This procedure could provide a way of embedding in the clinical workflow assistance in cancer diagnosis and treatment based on personalized information.

Published
2021

3. Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced: the PUMA trial

Author

Regnery, Sebastian, de Colle, Chiara, Eze, Chukwuka, Corradini, Stefanie, Thieke, Christian, Sedlaczek, Oliver, Schlemmer, Heinz-Peter, Dinkel, Julien, Seith, Ferdinand, Kopp-Schneider, Annette, Gillmann, Clarissa, Renkamp, C. Katharina, Landry, Guillaume, Thorwarth, Daniela, Zips, Daniel, Belka, Claus, Jäkel, Oliver, Debus, Jürgen, and Hörner-Rieber, Juliane

Published
2023
Full Text
View/download PDF

4. Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task force

Author

Sedlaczek, Oliver Lukas, Kleesiek, Jens, Gallagher, Ferdia A., Murray, Jacob, Prinz, Sebastian, Perez-Lopez, Raquel, Sala, Evia, Caramella, Caroline, Diffetock, Sebastian, Lassau, Nathalie, Priest, Andrew N., Suzuki, Chikako, Vargas, Roberto, Giandini, Tommaso, Vaiani, Marta, Messina, Antonella, Blomqvist, Lennart K., Beets-Tan, Regina G. H., Oberrauch, Petra, Schlemmer, Heinz-Peter, and Bach, Michael

Published
2022
Full Text
View/download PDF

5. Navigator‐based motion compensation for liver BOLD measurement with five‐echo SAGE EPI and breath‐hold task.

Author

Zhang, Ke, Triphan, Simon M. F., Wielpütz, Mark O., Ziener, Christian H., Ladd, Mark E., Schlemmer, Heinz‐Peter, Kauczor, Hans‐Ulrich, Sedlaczek, Oliver, and Kurz, Felix T.

Subjects
OXYGEN in the blood, HYPERVARIABLE regions, SPATIAL resolution, LIVER, NET Asset Value
Abstract

Purpose: The purpose of this work is to apply multi‐echo spin‐ and gradient‐echo (SAGE) echo‐planar imaging (EPI) combined with a navigator‐based (NAV) prospective motion compensation method for a quantitative liver blood oxygen level dependent (BOLD) measurement with a breath‐hold (BH) task. Methods: A five‐echo SAGE sequence was developed to quantitatively measure T2 and T2* to depict function with sufficient signal‐to‐noise ratio, spatial resolution and sensitivity to BOLD changes induced by the BH task. To account for respiratory motion, a navigator was employed in the form of a single gradient‐echo projection readout, located at the diaphragm along the inferior–superior direction. Prior to each transverse imaging slice of the spin‐echo EPI‐based readouts, navigator acquisition and fat suppression were incorporated. Motion data was obtained from the navigator and transmitted back to the sequence, allowing real‐time adjustments to slice positioning. Six healthy volunteers and three patients with liver carcinoma were included in this study. Quantitative T2 and T2* were calculated at each time point of the BH task. Parameters of t value from first‐level analysis using a general linear model and hepatovascular reactivity (HVR) of Echo1, T2 and T2* were calculated. Results: The motion caused by respiratory activity was successfully compensated using the navigator signal. The average changes of T2 and T2* during breath‐hold were about 1% and 0.7%, respectively. With the help of NAV prospective motion compensation whole liver t values could be obtained without motion artifacts. The quantified liver T2 (34.7 ± 0.7 ms) and T2* (29 ± 1.2 ms) values agreed with values from literature. In healthy volunteers, the distribution of statistical t value and HVR was homogeneous throughout the whole liver. In patients with liver carcinoma, the distribution of t value and HVR was inhomogeneous due to metastases or therapy. Conclusions: This study demonstrates the feasibility of using a NAV prospective motion compensation technique in conjunction with five‐echo SAGE EPI for the quantitative measurement of liver BOLD with a BH task. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Author

van Tilburg, Cornelis M., Witt, Ruth, Heiss, Melanie, Pajtler, Kristian W., Plass, Christoph, Poschke, Isabel, Platten, Michael, Harting, Inga, Sedlaczek, Oliver, Freitag, Angelika, Meyrath, David, Taylor, Lenka, Balasubramanian, Gnana Prakash, Jäger, Natalie, Pfaff, Elke, Jones, Barbara C., Milde, Till, Pfister, Stefan M., Jones, David T. W., Kopp-Schneider, Annette, and Witt, Olaf

Published
2020
Full Text
View/download PDF

10. Correction : Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced non-small cell lung cancer: the PUMA trial

Author

Regnery, Sebastian, primary, de Colle, Chiara, additional, Eze, Chukwuka, additional, Corradini, Stefanie, additional, Thieke, Christian, additional, Sedlaczek, Oliver, additional, Schlemmer, Heinz-Peter, additional, Dinkel, Julien, additional, Seith, Ferdinand, additional, Kopp-Schneider, Annette, additional, Gillmann, Clarissa, additional, Renkamp, C. Katharina, additional, Landry, Guillaume, additional, Thorwarth, Daniela, additional, Zips, Daniel, additional, Belka, Claus, additional, Jäkel, Oliver, additional, Debus, Jürgen, additional, and Hörner-Rieber, Juliane, additional

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 1 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Author

Hajda, Jacek, primary, Leuchs, Barbara, primary, Angelova, Assia L., primary, Frehtman, Veronika, primary, Rommelaere, Jean, primary, Mertens, Mieke, primary, Pilz, Maximilian, primary, Kieser, Meinhard, primary, Krebs, Ottheinz, primary, Dahm, Michael, primary, Huber, Bernard, primary, Engeland, Christine E., primary, Mavratzas, Athanasios, primary, Hohmann, Nicolas, primary, Schreiber, Jutta, primary, Jäger, Dirk, primary, Halama, Niels, primary, Sedlaczek, Oliver, primary, Gaida, Matthias M., primary, Daniel, Volker, primary, Springfeld, Christoph, primary, and Ungerechts, Guy, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 2 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Author

Hajda, Jacek, primary, Leuchs, Barbara, primary, Angelova, Assia L., primary, Frehtman, Veronika, primary, Rommelaere, Jean, primary, Mertens, Mieke, primary, Pilz, Maximilian, primary, Kieser, Meinhard, primary, Krebs, Ottheinz, primary, Dahm, Michael, primary, Huber, Bernard, primary, Engeland, Christine E., primary, Mavratzas, Athanasios, primary, Hohmann, Nicolas, primary, Schreiber, Jutta, primary, Jäger, Dirk, primary, Halama, Niels, primary, Sedlaczek, Oliver, primary, Gaida, Matthias M., primary, Daniel, Volker, primary, Springfeld, Christoph, primary, and Ungerechts, Guy, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 4 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Author

Hajda, Jacek, primary, Leuchs, Barbara, primary, Angelova, Assia L., primary, Frehtman, Veronika, primary, Rommelaere, Jean, primary, Mertens, Mieke, primary, Pilz, Maximilian, primary, Kieser, Meinhard, primary, Krebs, Ottheinz, primary, Dahm, Michael, primary, Huber, Bernard, primary, Engeland, Christine E., primary, Mavratzas, Athanasios, primary, Hohmann, Nicolas, primary, Schreiber, Jutta, primary, Jäger, Dirk, primary, Halama, Niels, primary, Sedlaczek, Oliver, primary, Gaida, Matthias M., primary, Daniel, Volker, primary, Springfeld, Christoph, primary, and Ungerechts, Guy, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 1 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Author

Hajda, Jacek, primary, Leuchs, Barbara, primary, Angelova, Assia L., primary, Frehtman, Veronika, primary, Rommelaere, Jean, primary, Mertens, Mieke, primary, Pilz, Maximilian, primary, Kieser, Meinhard, primary, Krebs, Ottheinz, primary, Dahm, Michael, primary, Huber, Bernard, primary, Engeland, Christine E., primary, Mavratzas, Athanasios, primary, Hohmann, Nicolas, primary, Schreiber, Jutta, primary, Jäger, Dirk, primary, Halama, Niels, primary, Sedlaczek, Oliver, primary, Gaida, Matthias M., primary, Daniel, Volker, primary, Springfeld, Christoph, primary, and Ungerechts, Guy, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 4 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Author

Hajda, Jacek, primary, Leuchs, Barbara, primary, Angelova, Assia L., primary, Frehtman, Veronika, primary, Rommelaere, Jean, primary, Mertens, Mieke, primary, Pilz, Maximilian, primary, Kieser, Meinhard, primary, Krebs, Ottheinz, primary, Dahm, Michael, primary, Huber, Bernard, primary, Engeland, Christine E., primary, Mavratzas, Athanasios, primary, Hohmann, Nicolas, primary, Schreiber, Jutta, primary, Jäger, Dirk, primary, Halama, Niels, primary, Sedlaczek, Oliver, primary, Gaida, Matthias M., primary, Daniel, Volker, primary, Springfeld, Christoph, primary, and Ungerechts, Guy, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 3 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Author

Hajda, Jacek, primary, Leuchs, Barbara, primary, Angelova, Assia L., primary, Frehtman, Veronika, primary, Rommelaere, Jean, primary, Mertens, Mieke, primary, Pilz, Maximilian, primary, Kieser, Meinhard, primary, Krebs, Ottheinz, primary, Dahm, Michael, primary, Huber, Bernard, primary, Engeland, Christine E., primary, Mavratzas, Athanasios, primary, Hohmann, Nicolas, primary, Schreiber, Jutta, primary, Jäger, Dirk, primary, Halama, Niels, primary, Sedlaczek, Oliver, primary, Gaida, Matthias M., primary, Daniel, Volker, primary, Springfeld, Christoph, primary, and Ungerechts, Guy, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table 2 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Author

Hajda, Jacek, primary, Leuchs, Barbara, primary, Angelova, Assia L., primary, Frehtman, Veronika, primary, Rommelaere, Jean, primary, Mertens, Mieke, primary, Pilz, Maximilian, primary, Kieser, Meinhard, primary, Krebs, Ottheinz, primary, Dahm, Michael, primary, Huber, Bernard, primary, Engeland, Christine E., primary, Mavratzas, Athanasios, primary, Hohmann, Nicolas, primary, Schreiber, Jutta, primary, Jäger, Dirk, primary, Halama, Niels, primary, Sedlaczek, Oliver, primary, Gaida, Matthias M., primary, Daniel, Volker, primary, Springfeld, Christoph, primary, and Ungerechts, Guy, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table 3 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Author

Hajda, Jacek, primary, Leuchs, Barbara, primary, Angelova, Assia L., primary, Frehtman, Veronika, primary, Rommelaere, Jean, primary, Mertens, Mieke, primary, Pilz, Maximilian, primary, Kieser, Meinhard, primary, Krebs, Ottheinz, primary, Dahm, Michael, primary, Huber, Bernard, primary, Engeland, Christine E., primary, Mavratzas, Athanasios, primary, Hohmann, Nicolas, primary, Schreiber, Jutta, primary, Jäger, Dirk, primary, Halama, Niels, primary, Sedlaczek, Oliver, primary, Gaida, Matthias M., primary, Daniel, Volker, primary, Springfeld, Christoph, primary, and Ungerechts, Guy, primary

Published
2023
Full Text
View/download PDF

26. Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced non-small-cell lung cancer: the PUMA trial.

Author

Regnery, Sebastian, de Colle, Chiara, Eze, Chukwuka, Corradini, Stefanie, Thieke, Christian, Sedlaczek, Oliver, Schlemmer, Heinz-Peter, Dinkel, Julien, Seith, Ferdinand, Kopp-Schneider, Annette, Gillmann, Clarissa, Renkamp, C. Katharina, Landry, Guillaume, Thorwarth, Daniela, Zips, Daniel, Belka, Claus, Jäkel, Oliver, Debus, Jürgen, and Hörner-Rieber, Juliane

Subjects
NON-small-cell lung carcinoma, RADIOTHERAPY, CHEMORADIOTHERAPY, LINEAR accelerators, MAGNETIC resonance imaging, MAGNETIC resonance
Abstract

Background: Patients with locally-advanced non-small-cell lung cancer (LA-NSCLC) are often ineligible for surgery, so that definitive chemoradiotherapy (CRT) represents the treatment of choice. Nevertheless, long-term tumor control is often not achieved. Intensification of radiotherapy (RT) to improve locoregional tumor control is limited by the detrimental effect of higher radiation exposure of thoracic organs-at-risk (OAR). This narrow therapeutic ratio may be expanded by exploiting the advantages of magnetic resonance (MR) linear accelerators, mainly the online adaptation of the treatment plan to the current anatomy based on daily acquired MR images. However, MR-guidance is both labor-intensive and increases treatment times, which raises the question of its clinical feasibility to treat LA-NSCLC. Therefore, the PUMA trial was designed as a prospective, multicenter phase I trial to demonstrate the clinical feasibility of MR-guided online adaptive RT in LA-NSCLC. Methods: Thirty patients with LA-NSCLC in stage III A-C will be accrued at three German university hospitals to receive MR-guided online adaptive RT at two different MR-linac systems (MRIdian Linac®, View Ray Inc. and Elekta Unity®, Elekta AB) with concurrent chemotherapy. Conventionally fractioned RT with isotoxic dose escalation up to 70 Gy is applied. Online plan adaptation is performed once weekly or in case of major anatomical changes. Patients are followed-up by thoracic CT- and MR-imaging for 24 months after treatment. The primary endpoint is twofold: (1) successfully completed online adapted fractions, (2) on-table time. Main secondary endpoints include adaptation frequency, toxicity, local tumor control, progression-free and overall survival. Discussion: PUMA aims to demonstrate the clinical feasibility of MR-guided online adaptive RT of LA-NSCLC. If successful, PUMA will be followed by a clinical phase II trial that further investigates the clinical benefits of this approach. Moreover, PUMA is part of a large multidisciplinary project to develop MR-guidance techniques. Trial registration: ClinicalTrials.gov: NCT05237453. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Phase I results of the INFORM2 combination study of nivolumab and entinostat in children and adolescents: INFORM2 NivEnt.

Author

van Tilburg, Cornelis Martinus, primary, Heiss, Melanie, additional, Øra, Ingrid, additional, Beilken, Andreas, additional, Dirksen, Uta, additional, Gottardo, Nicholas G., additional, Khuong-Quang, Dong-Anh, additional, Hansford, Jordan, additional, Hutter, Caroline, additional, Van der Lugt, Jasper, additional, Thorwarth, Anne, additional, Poschke, Isabel, additional, Harting, Inga, additional, Sedlaczek, Oliver, additional, Beck, Pengbo, additional, Freitag, Angelika, additional, Jones, David T.W., additional, Jäger, Natalie, additional, Kopp-Schneider, Annette, additional, and Witt, Olaf, additional

Published
2022
Full Text
View/download PDF

30. Interdisziplinäre radiologische Konsolidierungsbeurteilung von Pseudarthrosen: Reicht ein Röntgenbild aus?

Author

Speicher, Anna, Tanner, Michael, Heller, Raban, Sedlaczek, Oliver, Sprengel, Simon David, Haubruck, Patrick, Schmidmaier, Gerhard, and Miska, Matthias

Subjects
Röntgen, Pseudarthrose, ddc: 610, Knochenbruchheilung, Medicine and health, Bildgebung, Computertomographie
Abstract

Fragestellung: Summationseffekte durch Projektion in die Ebene, Kallusbildung und Überlagerungen (Fremdmaterial) erschweren die Beurteilung von Pseudarthrosen. Die Computertomographie (bei hoher Strahlenbelastung) wird aktuell als Goldstandard angenommen, jedoch nicht standardisiert eingesetzt. [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2021

32. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Author

Hajda, Jacek, primary, Leuchs, Barbara, additional, Angelova, Assia L., additional, Frehtman, Veronika, additional, Rommelaere, Jean, additional, Mertens, Mieke, additional, Pilz, Maximilian, additional, Kieser, Meinhard, additional, Krebs, Ottheinz, additional, Dahm, Michael, additional, Huber, Bernard, additional, Engeland, Christine E., additional, Mavratzas, Athanasios, additional, Hohmann, Nicolas, additional, Schreiber, Jutta, additional, Jäger, Dirk, additional, Halama, Niels, additional, Sedlaczek, Oliver, additional, Gaida, Matthias M., additional, Daniel, Volker, additional, Springfeld, Christoph, additional, and Ungerechts, Guy, additional

Published
2021
Full Text
View/download PDF

33. Additional file 3 of INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Author

Tilburg, Cornelis M. Van, Witt, Ruth, Heiss, Melanie, Pajtler, Kristian W., Plass, Christoph, Poschke, Isabel, Platten, Michael, Harting, Inga, Sedlaczek, Oliver, Freitag, Angelika, Meyrath, David, Taylor, Lenka, Gnana Prakash Balasubramanian, Jäger, Natalie, Pfaff, Elke, Jones, Barbara C., Milde, Till, Pfister, Stefan M., Jones, David T. W., Kopp-Schneider, Annette, and Witt, Olaf

Abstract

Additional file 3. Combination treatment modifications.

Published
2020
Full Text
View/download PDF

34. Additional file 1 of INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Author

Tilburg, Cornelis M. Van, Witt, Ruth, Heiss, Melanie, Pajtler, Kristian W., Plass, Christoph, Poschke, Isabel, Platten, Michael, Harting, Inga, Sedlaczek, Oliver, Freitag, Angelika, Meyrath, David, Taylor, Lenka, Gnana Prakash Balasubramanian, Jäger, Natalie, Pfaff, Elke, Jones, Barbara C., Milde, Till, Pfister, Stefan M., Jones, David T. W., Kopp-Schneider, Annette, and Witt, Olaf

Abstract

Additional file 1. Eligibility criteria

Published
2020
Full Text
View/download PDF

35. Additional file 4 of INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Author

Tilburg, Cornelis M. Van, Witt, Ruth, Heiss, Melanie, Pajtler, Kristian W., Plass, Christoph, Poschke, Isabel, Platten, Michael, Harting, Inga, Sedlaczek, Oliver, Freitag, Angelika, Meyrath, David, Taylor, Lenka, Gnana Prakash Balasubramanian, Jäger, Natalie, Pfaff, Elke, Jones, Barbara C., Milde, Till, Pfister, Stefan M., Jones, David T. W., Kopp-Schneider, Annette, and Witt, Olaf

Subjects
Data_FILES
Abstract

Additional file 4. Visit plan.

Published
2020
Full Text
View/download PDF

36. Additional file 2 of INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Author

Tilburg, Cornelis M. Van, Witt, Ruth, Heiss, Melanie, Pajtler, Kristian W., Plass, Christoph, Poschke, Isabel, Platten, Michael, Harting, Inga, Sedlaczek, Oliver, Freitag, Angelika, Meyrath, David, Taylor, Lenka, Gnana Prakash Balasubramanian, Jäger, Natalie, Pfaff, Elke, Jones, Barbara C., Milde, Till, Pfister, Stefan M., Jones, David T. W., Kopp-Schneider, Annette, and Witt, Olaf

Abstract

Additional file 2. Dose de-escalation table.

Published
2020
Full Text
View/download PDF

37. Joint Imaging Platform for Federated Clinical Data Analytics

Author

Scherer, Jonas, primary, Nolden, Marco, additional, Kleesiek, Jens, additional, Metzger, Jasmin, additional, Kades, Klaus, additional, Schneider, Verena, additional, Bach, Michael, additional, Sedlaczek, Oliver, additional, Bucher, Andreas M., additional, Vogl, Thomas J., additional, Grünwald, Frank, additional, Kühn, Jens-Peter, additional, Hoffmann, Ralf-Thorsten, additional, Kotzerke, Jörg, additional, Bethge, Oliver, additional, Schimmöller, Lars, additional, Antoch, Gerald, additional, Müller, Hans-Wilhelm, additional, Daul, Andreas, additional, Nikolaou, Konstantin, additional, la Fougère, Christian, additional, Kunz, Wolfgang G., additional, Ingrisch, Michael, additional, Schachtner, Balthasar, additional, Ricke, Jens, additional, Bartenstein, Peter, additional, Nensa, Felix, additional, Radbruch, Alexander, additional, Umutlu, Lale, additional, Forsting, Michael, additional, Seifert, Robert, additional, Herrmann, Ken, additional, Mayer, Philipp, additional, Kauczor, Hans-Ulrich, additional, Penzkofer, Tobias, additional, Hamm, Bernd, additional, Brenner, Winfried, additional, Kloeckner, Roman, additional, Düber, Christoph, additional, Schreckenberger, Mathias, additional, Braren, Rickmer, additional, Kaissis, Georgios, additional, Makowski, Marcus, additional, Eiber, Matthias, additional, Gafita, Andrei, additional, Trager, Rupert, additional, Weber, Wolfgang A., additional, Neubauer, Jakob, additional, Reisert, Marco, additional, Bock, Michael, additional, Bamberg, Fabian, additional, Hennig, Jürgen, additional, Meyer, Philipp Tobias, additional, Ruf, Juri, additional, Haberkorn, Uwe, additional, Schoenberg, Stefan O., additional, Kuder, Tristan, additional, Neher, Peter, additional, Floca, Ralf, additional, Schlemmer, Heinz-Peter, additional, and Maier-Hein, Klaus, additional

Published
2020
Full Text
View/download PDF

43. Towards quantitative perfusion MRI of the lung in COPD: The problem of short-term repeatability

Author

Ter-Karapetyan, Alvard, Triphan, Simon M. F., Jobst, Bertram J., Anjorin, Angela F., Ley-Zaporozhan, Julia, Ley, Sebastian, Sedlaczek, Oliver, Biederer, Jürgen, Kauczor, Hans-Ulrich, Jakob, Peter M., and Wielpütz, Mark O.

Subjects
Male, Pulmonology, Imaging Techniques, Physiology, Science, Chronic Obstructive Pulmonary Disease, Amperometry, Pulmonary Function, Hyperoxia, Research and Analysis Methods, Pathology and Laboratory Medicine, Diagnostic Radiology, Automation, Pulmonary Disease, Chronic Obstructive, Signs and Symptoms, Diagnostic Medicine, Blood Flow, Image Interpretation, Computer-Assisted, Medicine and Health Sciences, Humans, Lung, Bioelectrochemical Analysis, Aged, Blood Volume, Radiology and Imaging, Biology and Life Sciences, Reproducibility of Results, Middle Aged, Magnetic Resonance Imaging, Pulmonary Imaging, Body Fluids, Oxygen, Bioassays and Physiological Analysis, Blood, Medicine, Female, Anatomy, Biochemical Analysis, Magnetic Resonance Angiography, Software, Research Article
Abstract

Purpose4D perfusion magnetic resonance imaging (MRI) with intravenous injection of contrast agent allows for a radiation-free assessment of regional lung function. It is therefore a valuable method to monitor response to treatment in patients with chronic obstructive pulmonary disease (COPD). This study was designed to evaluate its potential for monitoring short-term response to hyperoxia in COPD patients.Materials and methods19 prospectively enrolled COPD patients (median age 66y) underwent paired dynamic contrast-enhanced 4D perfusion MRI within 35min, first breathing 100% oxygen (injection 1, O2) and then room air (injection 2, RA), which was repeated on two consecutive days (day 1 and 2). Post-processing software was employed to calculate mean transit time (MTT), pulmonary blood volume (PBV) and pulmonary blood flow (PBF), based on the indicator dilution theory, for the automatically segmented whole lung and 12 regions of equal volume.ResultsComparing O2 with RA conditions, PBF and PBV were found to be significantly lower at O2, consistently on both days (pConclusionThe second injection (RA) yielded higher PBF and PBV, which apparently contradicts the established hypothesis that hyperoxia increases lung perfusion. Quantification of 4D perfusion MRI by current software approaches may thus be limited by residual circulating contrast agent in the short-term and even the next day.

Published
2018

44. INFORM2 exploratory multinational phase I/II combination study of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies: INFORM2 NivEnt.

Author

van Tilburg, Cornelis Martinus, primary, Witt, Ruth, additional, Pajtler, Kristian W., additional, Christoph, Plass, additional, Poschke, Isabel, additional, Platten, Michael, additional, Harting, Inga, additional, Sedlaczek, Oliver, additional, Freitag, Angelika, additional, Meyrath, David, additional, Taylor, Lenka, additional, Balasubramanian, Gnana Prakash, additional, Jäger, Natalie, additional, Pfaff, Elke, additional, Worst, Barbara Christine, additional, Milde, Till, additional, Pfister, Stefan M., additional, Jones, David T. W., additional, Kopp-Schneider, Annette, additional, and Witt, Olaf, additional

Published
2019
Full Text
View/download PDF

46. Tumor Cell Load and Heterogeneity Estimation From Diffusion-Weighted MRI Calibrated With Histological Data: an Example From Lung Cancer

Author

Yin, Yi, primary, Sedlaczek, Oliver, additional, Muller, Benedikt, additional, Warth, Arne, additional, Gonzalez-Vallinas, Margarita, additional, Lahrmann, Bernd, additional, Grabe, Niels, additional, Kauczor, Hans-Ulrich, additional, Breuhahn, Kai, additional, Vignon-Clementel, Irene E., additional, and Drasdo, Dirk, additional

Published
2018
Full Text
View/download PDF

47. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

Author

Hajda, Jacek, primary, Lehmann, Monika, additional, Krebs, Ottheinz, additional, Kieser, Meinhard, additional, Geletneky, Karsten, additional, Jäger, Dirk, additional, Dahm, Michael, additional, Huber, Bernard, additional, Schöning, Tilman, additional, Sedlaczek, Oliver, additional, Stenzinger, Albrecht, additional, Halama, Niels, additional, Daniel, Volker, additional, Leuchs, Barbara, additional, Angelova, Assia, additional, Rommelaere, Jean, additional, Engeland, Christine E., additional, Springfeld, Christoph, additional, and Ungerechts, Guy, additional

Published
2017
Full Text
View/download PDF

48. Reproducibility and comparison of oxygen-enhanced T1 quantification in COPD and asthma patients

Author

Triphan, Simon M. F., primary, Jobst, Bertram J., additional, Anjorin, Angela, additional, Sedlaczek, Oliver, additional, Wolf, Ursula, additional, Terekhov, Maxim, additional, Hoffmann, Christian, additional, Ley, Sebastian, additional, Düber, Christoph, additional, Biederer, Jürgen, additional, Kauczor, Hans-Ulrich, additional, Jakob, Peter M., additional, and Wielpütz, Mark O., additional

Published
2017
Full Text
View/download PDF

50. Additional file 4: of Muscarinic M1 receptors modulate endotoxemia-induced loss of synaptic plasticity

Author

Zivkovic, Aleksandar, Sedlaczek, Oliver, Haken, Rebecca Von, Schmidt, Karsten, Brenner, Thorsten, Weigand, Markus, Bading, Hilmar, C. Bengtson, and Hofer, Stefan

Subjects
nervous system
Abstract

Physostigmine without preincubation fails to rescue LTP induced by LPS treatment. Time series plots as described in the Fig. 4 but with physostigmine (a: 5 μM, n = 3 cells; b: 10 μM n = 2 cells) applied only during the recordings without preincubation. (PDF 265 kb)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results